Entera Bio (ENTX)
(Delayed Data from NSDQ)
$1.79 USD
+0.01 (0.56%)
Updated Nov 5, 2024 03:59 PM ET
After-Market: $1.78 -0.01 (-0.56%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Price, Consensus and EPS Surprise
ENTX 1.79 +0.01(0.56%)
Will ENTX be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for ENTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ENTX
Are Medical Stocks Lagging Argenx (ARGX) This Year?
ENTX & OPK Stock May Gain Following Positive PK/PD Research Data
ENTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Entera Bio (ENTX) Stock Outpacing Its Medical Peers This Year?
Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?
All You Need to Know About Entera Bio (ENTX) Rating Upgrade to Buy
Other News for ENTX
Buy Rating Affirmed for Entera Bio’s EB613: A Game Changer in Osteoporosis Treatment
Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders
Entera Bio to Participate in Upcoming Investor and Scientific Conferences
ENTX Stock Earnings: Entera Bio Meets EPS for Q2 2024
Entera Bio Receives Strong Buy Rating Amid Anticipated FDA Ruling and Pipeline Progress